Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5&lt;i&gt;H&lt;/i&gt;-pyrrolo[3,4-&lt;i&gt;d&lt;/i&gt;]pyrimidine-based PARP1/ATR dual inhibitors. This evidence concerns the gene PARP1 and breast carcinoma.